Back to Pressroom

Baltimore, MD | Monday, June 01, 2009

Champions Biotechnology, Inc. Launches Personalized Cancer Treatment.com

Oct 25 2011 10:16 AM

Website Features Exclusive Personalized Cancer Treatment Options For Cancer Patients And Healthcare Professionals

(OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has launched the website PersonalizedCancerTreatment.com. The website provides information and access to the company’s unparalleled personalized treatment options for physicians and their patients, including: Champions Biotechnology, Inc.

Personalized Tumorgraft™

A Personalized Tumorgraft is a sample of the patient’s living tumor that is grown and tested in Champions’ facilities. This novel approach optimizes treatment choices through simultaneous evaluation of the effectiveness of numerous anti-cancer drugs, sparing the patient from undergoing therapy that may not be optimal for that specific cancer. Champions also maintains the patient’s living Tumorgraft to allow for future studies, if needed, for the patient and his/her family.

Personalized Vaccine™

A therapeutic cancer vaccine may be developed from the patient’s tumor to provide the most personalized cancer treatment available. Tumor cells from the Personalized Tumorgraft are genetically modified, then used to stimulate a patient’s immune system to recognize and, if possible, attack the patient’s cancer cells.

Personalized Oncology Panel™

Champions’ provides the cancer patient and treating physician with access to the world’s top cancer experts, convening exclusive panels of renowned experts, selected based on a patient’s specific cancer type and condition, from each of the disciplines critical to the patient’s case. In a round table forum, the expert panel debates the broad array of options and provides a consensus treatment recommendation to the patient’s physician.

The website also includes a selection of case presentations in the Healthcare Professional section that demonstrate the positive clinical results achieved by physicians whose cancer patients have chosen to use Champions’ services.

“With the launch of our new website, Champions empowers Web users to explore, learn, and expand their understanding of breakthrough cancer treatments, making available today the personalized oncology options of tomorrow,” said Doug Burkett, PhD, President of Champions Biotechnology, Inc. “We are providing patients and physicians with real-time access to cutting edge medicine, including valuable insight into the most promising new cancer treatments, genetic tests, novel therapeutics, landmark research, and more.”

Dr. Burkett continued, “Champions offers a more precise approach to cancer treatment, because every patient’s cancer is unique. In partnership with one’s physician, Champions optimizes a given treatment plan’s potential for success and maximizes the patient’s most precious resource: time. We anticipate the launch of PersonalizedCancerTreatment.com will bring our exceptional spectrum of personalized cancer treatment options to a broader audience than ever before.”

To learn more about Personalized Cancer Treatment please visit www.personalizedcancertreatment.com.

For more news and information on Champions Biotechnology, Inc., please visit www.IRGnews.com/coi/CSBR where you can find the CEO’s video, a fact sheet on the company, investor presentations, and more.

About Champions Oncology, Inc.

Champions Oncology, Inc. (formerly Champions Biotechnology, Inc) is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s Tumorgraft™ Technology Platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Tumorgrafts™, in a manner that preserves the biological characteristics of the original human tumor. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions (“POS”) in which physicians and patients looking for information help guide the development of personalized treatment plans, and Translational Oncology Solutions (“TOS”) in which pharmaceutical and biotech companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs and increasing the adoption of existing drugs. The Company’s Tumorgraft™ Technology Platform consists of processes, physical tumors and information that we use to personalize the development and use of oncology drugs. The Company is building its Tumorgraft™ Technology Platform through the procurement, development and characterization of numerous Tumorgrafts™ within each of several cancer types. Tumorgrafts™ are procured through agreements with a number of institutions in the U.S. and overseas as well as through its POS business. The Tumorgrafts™ are developed and tested through agreement with a United States-based preclinical facility.

The Company provides POS to oncologists by establishing and administering expert tumor panels for their patients to analyze medical records and test results, to assist in understanding conventional and experimental options and to identify and arrange for testing, analysis and study of the patients’ cancer tissues, as appropriate. Additionally, the Company offers Personalized Tumorgraft™ development, drug studies and genome sequencing as part of its POS whereby physicians can evaluate the effects of cancer drugs on their patients’ tumorgrafts and understand the genetic make-up of their patient’s tumor enabling them to better select treatment regimens that may be efficacious to the patient

This press release may contain “forward-looking statements” (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as “believe,” “may,” “could,” “will,” “intend,” “expect,” “anticipate,” “plan,” and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company’s actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology’s Form 10-K for the fiscal year ended April 30, 2011 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology’s future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology’s expectations, except as required by law.

References:

  1. Hidalgo M et al. Activity of gemcitabine in direct patient derived xenografts predicts clinical outcome: validation of an in vivo model for drug development. J Clin Oncol 27:15s, 2009 (suppl; abstr 4528)
  2. Hidalgo M et al. A Pilot Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Mol Cancer Ther August 2011 10:1311-1316
  3. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006;12:4652-4661.
  4. Champions data on file.